Showing 1 - 3 results of 3 for search 'Sebastian Meerwein', query time: 0.01s Refine Results
  1. 1
    Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND

    Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND by Ronald F van Vollenhoven, Roy Fleischmann, Stephen Hall, Yanna Song, Sebastian Meerwein, Alvin F Wells, Oishi Tanjinatus

    Published 2024-09-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study

    Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-B... by Roy Fleischmann, Stephen Hall, Bernard Combe, Andrea Rubbert-Roth, Christina Charles-Schoeman, Nasser Khan, Heidi S Camp, Sebastian Meerwein, Kyle M Carter

    Published 2024-07-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study

    Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study by Josef S Smolen, Yoshiya Tanaka, Paul Emery, Manish Jain, Koji Kato, Stanley B Cohen, Nasser Khan, William Rigby, Sebastian Meerwein, Juan Ignacio Vargas, Kyle M Carter, Charles Phillips

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: